The contemporary clinical landscape of gastrointestinal stromal tumor (GIST) has evolved rapidly over the past several years. Widely used treatment guidelines – from the European Society of ...

Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, Dortmund 44227, ...

The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and ...

IHCA (CD117, CD34, vimentin, smooth muscle actin (SMA), S-100, Discovered On GIST 1 (DOG1)), TKI therapy and outcome. Survival outcome in terms of overall survival (OS), relapse-free survival (RFS ...

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft ...

Combining surgery with chemotherapy significantly improves survival in GIST patients with liver metastases compared to chemotherapy alone. Median CSS and OS for combined treatment exceed 120 months, ...

Multi-target approach counters tumor growth in several cancers Date: January 16, 2025 Source: Yale University Summary: The tissue adjacent to a tumor behaves differently than areas farther away ...

The tissue adjacent to a tumor behaves differently than areas farther away: The tumor’s cancerous cells influence their surroundings, blocking the body’s immune defenses and creating a sort of haven ...

Accurate diagnosis necessitates meticulous histological examination and immunostaining for relevant markers. MGTs are highly aggressive and associated with a poor prognosis. Complete surgical ...

Nonadherence to Gleevec in GIST patients is common, with cognitive functioning, TDM, and social support as key indicators. A machine learning model using 64 covariates identified 19 significant ...